The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2018 | Prognostic markers and MRD in CLL
Robin Foà
• 25 Oct 2018
Speaking from the European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) International Meeting 2018, held in Barcelona, Spain, Robin Foà, MD, of the Sapienza University of Rome, Rome, Italy, discusses the key prognostic markers and measurable residual disease in chronic lymphocytic leukemia.
